Welcome to our dedicated page for EyePoint SEC filings (Ticker: EYPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The EyePoint, Inc. (EYPT) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, offering detailed insight into this clinical-stage biopharmaceutical company focused on serious retinal diseases. EyePoint’s filings, including multiple Form 8-K reports, document material events such as clinical milestones, equity offerings, and corporate actions related to its lead investigational product, DURAVYU™ (vorolanib intravitreal insert).
Through these filings, investors can review clinical development updates formally reported to the SEC, such as the completion of enrollment in the pivotal Phase 3 LUGANO and LUCIA trials in wet age-related macular degeneration, positive recommendations from the independent Data Safety Monitoring Committee, and the announcement of a pivotal Phase 3 program in diabetic macular edema (COMO and CAPRI). Filings also reference the posting of investor presentations that summarize estimated cash and investments and outline EyePoint’s development plans.
EyePoint’s SEC documents further detail capital markets activity, including an underwriting agreement and public offering of common stock and pre-funded warrants, as well as a Controlled Equity Offering Sales Agreement for at-the-market issuances. These filings describe the terms of offerings, net proceeds, intended use of funds to advance DURAVYU in wet AMD and DME, and the legal opinions related to the validity of issued securities.
Additional filings cover corporate governance and compensation matters, such as amendments to the 2023 Long-Term Incentive Plan, inducement grants to new employees under Nasdaq Listing Rule 5635(c)(4), and the results of stockholder votes at the annual meeting. Risk factors and forward-looking statement sections referenced in filings highlight regulatory interactions, including an FDA warning letter pertaining to EyePoint’s Watertown manufacturing facility and an August 2022 subpoena from the U.S. Attorney’s Office for the District of Massachusetts.
On Stock Titan, EyePoint’s SEC filings are paired with AI-powered summaries that help explain the significance of each document, from 8-K current reports to registration-related filings. This allows readers to quickly understand how new offerings, clinical disclosures, or governance changes may relate to EyePoint’s development of DURAVYU and its broader ophthalmic pipeline, while still having direct access to the full text of each filing as made available through EDGAR.
Schedule 13G/A (Amendment 1) filed for EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) discloses that Federated Hermes, Inc. and related reporting persons—Voting Shares Irrevocable Trust, Thomas R. Donahue, Ann C. Donahue and J. Christopher Donahue—collectively hold 4,599,450 shares of EyePoint common stock, representing 6.68 % of the outstanding class as of 30 June 2025.
The filing is made under Rule 13d-1(b) indicating a passive investment. Federated Hermes has sole voting and dispositive power over all reported shares; the individual Donahues share voting/dispositive power through the Trust. No other parties share control, and the group certifies the stake was acquired in the ordinary course of business with no intent to influence control of the issuer.
Key details for investors:
- Ownership threshold: Stake exceeds the 5 % reporting trigger, signalling meaningful institutional involvement.
- Aggregation structure: Shares are held via a Pennsylvania-based trust controlled by Federated Hermes executives, consolidating voting power.
- Certification: Reporting persons affirm the investment is non-activist and purely passive.
No financial performance data, purchase price or transaction timing beyond the “Date of Event” are provided.
EyePoint Pharmaceuticals President, CEO, and Director Jay S. Duker reported a significant insider transaction on June 23, 2025. The transaction involved the sale of 56,665 shares of common stock at $8.21 per share to the Duker Family 2024 Irrevocable Trust in exchange for a promissory note valued at $465,219.65.
Following the transaction, Duker directly owns 986 shares and indirectly holds 99,165 shares through the Family Trust. The trust is managed by Duker's spouse as trustee and benefits their children. Notably, Duker has disclaimed beneficial ownership of the trust's securities.
Key transaction details:
- Transaction was executed under code 'J' (Other)
- Sale price determined by averaging high/low trading prices on transaction date
- Transaction represents a restructuring of ownership rather than a market sale
- Filing was signed by Ron Honig as Attorney-in-Fact on June 25, 2025